amidst
grow
need
better
vaccin
technolog
emerg
infecti
threat
antigen
adjuv
deliveri
synthet
nanoparticl
shown
much
promis
toward
improv
vaccin
safeti
particul
vaccin
engin
nanoscal
multival
antigen
antigenadjuv
promot
immun
cell
engag
antigen
process
howev
reliabl
coupl
antigen
danger
signal
fashion
remain
challeng
nanoscal
task
demand
stabl
adjuv
compartment
functionaliz
nanocarri
antigen
associ
herein
demonstr
viral
hollow
polymer
nanoparticl
encapsul
emerg
class
sting
stimul
interferon
gene
agonist
adjuv
viromimet
vaccin
platform
consist
thin
shell
poli
acid
plga
larg
aqueou
core
hollow
nanoparticl
stabli
entrap
solubl
adjuv
antigen
conjug
storag
owe
plga
hydrolysi
nanoparticl
readili
releas
adjuv
upon
cellular
uptak
facilit
immun
activ
antigen
recognit
knowledg
present
work
first
report
hollow
nanocarri
capabl
adjust
encapsul
control
releas
sting
agonist
vaccin
develop
local
endoplasm
reticulum
sting
potent
induc
type
interferon
ifn
typic
activ
upon
intracellular
follow
stimul
cytosol
cyclic
dinucleotid
cdn
sting
activ
turn
upregul
express
type
ifn
cytokin
shape
adapt
immun
qv
immun
activ
mechan
cdn
made
desir
adjuv
candid
improv
vaccin
potenc
howev
free
cdn
readili
system
distribut
may
trigger
undesir
reactogen
addit
given
type
ifn
pleiotrop
undermin
immun
respons
upon
antigen
cdn
deliveri
prefer
synchron
target
antigen
optim
immun
potenti
multipl
formul
prepar
cdn
shortcom
rang
poor
encapsul
effici
size
limit
carrier
instabl
leav
much
room
carrier
improv
light
consider
demonstr
hollow
polymer
nanoparticl
encapsul
tunabl
level
cdgmp
high
effici
improv
compound
potenc
safeti
surfac
function
nanoparticl
mediat
incorpor
polymer
shell
allow
antigen
conjug
vaccin
prepar
figur
present
studi
vaccin
middl
east
respiratori
syndrom
coronaviru
prepar
base
viromimet
design
pathogen
urgent
need
effect
sinc
first
isol
fatal
saudi
patient
continu
outbreak
report
case
across
countri
mortal
rate
close
relat
sever
acut
respiratori
syndrom
coronaviru
dromedari
camel
primari
reservoir
host
human
current
effect
therapeut
prophylact
measur
avail
diseas
vaccin
develop
remain
global
health
prioriti
identifi
world
health
organ
sever
vaccin
major
effort
vaccin
research
devot
subunit
candid
spike
protein
deriv
protein
receptor
bind
domain
rbd
safeti
logist
ongo
challeng
remain
howev
observ
pulmonari
immunopatholog
immun
challeng
host
rais
concern
use
tradit
addit
cellular
immun
increasingli
recogn
compon
alongsid
neutral
antibodi
durabl
protect
vaccin
may
benefit
technolog
effect
promot
humor
cellular
immun
respons
overcom
abovement
challeng
vaccin
develop
nanoparticl
vaccin
prepar
herein
integr
recombin
rbd
antigen
cyclic
diguanyl
monophosph
cdgmp
canon
sting
agonist
known
promot
immun
respons
cellular
immun
infecti
threat
rbd
nanoparticl
possess
morpholog
coordin
deliv
antigen
adjuv
vitro
vivo
comparison
formul
contain
solubl
antigen
adjuv
inocul
nanoparticl
np
vaccin
induc
greatli
enhanc
humor
cellular
respons
immun
mice
demonstr
immun
vaccin
confer
protect
lethal
challeng
highli
transgen
mice
global
express
human
dipeptidyl
peptidas
function
receptor
viromimet
nanoparticl
compris
entir
biocompat
materi
synthet
approach
afford
safe
viabl
strategi
bridg
effect
subunit
vaccin
also
provid
robust
versatil
platform
toward
address
public
health
demand
vaccin
develop
hollow
nanoparticl
prepar
use
doubl
emuls
process
da
plga
character
dynam
light
scatter
dl
analysi
reveal
hollow
nanoparticl
shell
thick
nm
unimod
particl
distribut
averag
diamet
nm
figur
larg
aqueou
interior
could
observ
success
encapsul
cdgmp
verifi
hplc
figur
hand
peak
cdgmp
detect
directli
mix
hollow
nanoparticl
cdgmp
indic
interact
nanoparticl
adjuv
figur
support
inform
differ
cdgmp
input
load
effici
consist
approxim
figur
result
indic
consist
partit
cdgmp
solut
insid
hollow
nanoparticl
regardless
cdgmp
concentr
therebi
enabl
control
adjuv
load
vaccin
develop
nanoparticl
np
cdgmp
highli
robust
littl
adjuv
releas
observ
extend
period
time
upon
storag
enclos
eppendorf
tube
room
temperatur
figur
support
inform
dialysi
experi
np
cdgmp
slowli
releas
adjuv
sustain
manner
ph
burst
releas
profil
ph
releas
kinet
could
attribut
ester
hydrolysi
plga
acid
condit
figur
releas
profil
favor
vaccin
deliveri
nanoparticl
retain
content
upon
administr
unload
cargo
enter
acid
endolysosom
compart
follow
cellular
uptak
structur
hollow
nanoparticl
reminisc
possess
nm
polymer
shell
larg
interior
aqueou
core
unlik
previous
report
formul
process
adopt
present
work
facilit
incorpor
nonioniz
compound
upon
adjust
doubl
emuls
paramet
observ
molecular
weight
polym
critic
hollow
nanostructur
format
prepar
da
plga
yield
solid
particl
particl
miniscul
aqueou
interior
observ
cryoem
figur
support
inform
consist
prior
report
plga
particl
poor
cdgmp
load
also
agreement
previou
unsuccess
effort
sting
agonist
encapsul
qv
reflect
challeng
nanoencapsul
nonlipophil
success
prepar
hollow
nanoparticl
made
possibl
da
polym
exhibit
significantli
lower
viscos
organ
solvent
compar
polym
figur
support
inform
given
correl
solut
viscos
surfac
reason
doubl
emuls
polym
solut
reduc
interfaci
surfac
tension
therebi
contribut
stabl
structur
highli
effici
incorpor
cdgmp
solut
subsequ
studi
np
cdgmp
contain
cdgmp
plga
appli
particular
formul
contain
approxim
cdgmp
molecul
per
particl
calcul
particl
number
measur
nanoparticl
track
analysi
particl
per
mg
polym
assess
immun
potenti
function
nanoparticul
sting
agonist
first
compar
cdgmp
np
cdgmp
vitro
studi
murin
dendrit
cell
dc
jaw
ii
cell
jaw
ii
cell
wide
use
immunolog
studi
due
eas
prepar
compar
primari
dendrit
though
slightli
less
respons
jaw
ii
cell
exhibit
similar
phenotyp
marker
function
bone
dendrit
cell
bmdc
use
fluoresc
label
cdgmp
note
cellular
uptak
water
solubl
sting
agonist
greatli
increas
encapsul
hollow
nanoparticl
figur
concomit
increas
induct
cytokin
includ
figur
capabl
cdgmp
np
cdgmp
induc
dc
matur
confirm
examin
upregul
costimulatori
molecul
bmdc
equival
adjuv
dosag
np
cdgmp
significantli
enhanc
express
bmdc
compar
free
cdgmp
figur
data
indic
np
cdgmp
superior
free
cdgmp
trigger
host
immun
respons
part
due
effici
uptak
profession
cell
verifi
advantag
np
cdgmp
promot
immun
activ
drain
lymph
node
prevent
undesir
even
harm
system
proinflammatori
respons
measur
level
poplit
lymph
node
sera
deriv
mice
prime
np
cdgmp
free
cdgmp
mice
treat
np
cdgmp
promin
level
within
drain
lymph
node
figur
yet
circul
significantli
subdu
compar
mice
receiv
free
cdgmp
figur
later
observ
like
indic
free
cdgmp
rapidli
diffus
blood
stream
upon
administr
subsequ
caus
unfavor
system
inflammatori
respons
data
suggest
np
cdgmp
preferenti
target
lymphat
system
ie
drain
lymph
node
prompt
local
immun
activ
reduc
system
reactogen
enabl
viral
mimicri
synthet
nanoparticl
well
provid
antigen
sourc
vaccin
recombin
rbd
protein
spike
antigen
produc
use
baculovir
express
system
figur
support
inform
purif
fplc
ident
rbd
protein
initi
verifi
size
approxim
kda
follow
western
blot
analysi
polyclon
antibodi
figur
support
inform
facilit
rbd
coupl
np
cdgmp
nanoparticl
prepar
outer
aqueou
phase
incorpor
effici
surfac
linker
approxim
yield
np
cdgmp
maleimid
linker
per
particl
neglig
influenc
cdgmp
encapsul
effici
figur
support
inform
chemistri
adopt
conjug
endogen
cystein
residu
rbd
protein
nanoparticl
surfac
follow
protein
conjug
size
nanoparticl
increas
nm
shift
mv
figur
c
polydispers
index
pdi
remain
constant
protein
conjug
mean
respect
figur
support
inform
quantif
bca
assay
show
nanoparticl
cdgmp
contain
antigen
input
rbd
per
mg
plga
approxim
particl
per
mg
plga
correspond
protein
antigen
per
particl
figur
figur
support
inform
imag
reveal
hollow
particul
structur
remain
intact
follow
protein
conjug
figur
note
nanoparticl
appear
solid
structur
upon
neg
stain
tem
uranyl
acet
preclud
enter
inner
core
indic
structur
integr
polymer
shell
figur
immunogold
stain
presenc
rbd
antigen
viromimet
nanoparticl
confirm
figur
also
observ
protein
conjug
process
littl
influenc
encapsul
adjuv
content
figur
highlight
particl
stabil
surfac
function
sinc
coordin
deliveri
antigen
danger
signal
fundament
attribut
viral
vaccin
shown
improv
subunit
antigen
evalu
antigen
adjuv
distribut
viromimet
nanoparticl
use
label
rbd
antigen
label
cdgmp
follow
h
incub
jaw
ii
cell
promin
antigen
adjuv
fluoresc
signal
observ
intracellularli
figur
high
magnif
coloc
antigen
adjuv
signal
evid
indic
viromimet
nanostructur
remain
stabl
medium
condit
cellular
uptak
examin
distribut
cdgmp
follow
subcutan
administr
mice
one
hour
nanoparticl
inject
coloc
antigen
adjuv
signal
observ
drain
lymph
node
examin
cell
subcapsular
sinu
sc
macrophag
respons
captur
recognit
virus
particul
show
larg
number
nanoparticl
coloc
gatekeep
cell
figur
distribut
nanoparticl
reminisc
previou
studi
show
coloc
viru
virion
sc
macrophag
drain
lymph
node
follow
footpad
observ
highlight
distribut
nanoparticl
synchron
lymph
node
deliveri
antigen
interiorli
load
adjuv
better
immun
cell
engag
antigen
present
determin
immunogen
nanoparticl
vaccin
group
mice
vaccin
subcutan
cdgmp
free
rbd
antigen
admix
free
cdgmp
free
rbd
antigen
admix
addavax
clinic
use
adjuv
influenza
vaccin
follow
vaccin
day
day
sera
collect
span
elisa
analysi
compar
group
cdgmp
induc
significantli
higher
titer
antibodi
reach
peak
two
week
postboost
sustain
figur
notabl
igg
subtyp
analysi
sera
collect
day
peak
antibodi
respons
show
high
level
antibodi
mice
immun
nanoparticl
vaccin
exhibit
balanc
respons
figur
contrast
free
rbd
antigen
induc
weak
respons
limit
level
respons
durabl
antibodi
titer
like
attribut
help
cell
next
investig
cell
respons
elicit
differ
vaccin
formul
cell
respons
acut
phase
first
determin
seven
day
booster
vaccin
restimul
harvest
splenocyt
purifi
rbd
follow
intracellular
stain
flow
cytometr
analysi
cdgmp
group
show
highest
frequenc
subset
correspond
function
cell
figur
moreov
week
postboost
transit
effector
cell
stabl
memori
cell
central
memori
phenotyp
also
significantli
elev
drain
lymph
node
cdgmp
mice
figur
cell
well
expand
central
memori
popul
elicit
viromimet
nanoparticl
thu
associ
augment
induct
rbd
antibodi
particularli
evalu
immun
shown
play
critic
role
confer
protect
infect
qv
sever
peptid
includ
identifi
valid
group
other
epitop
target
mhc
class
antigen
follow
stimul
splenocyt
pool
peptid
intracellular
mice
show
distinct
popul
cell
figur
indic
viromimet
nanoparticl
superior
induc
cytotox
cell
control
formul
dissect
nanoparticl
cell
respons
use
individu
synthet
peptid
found
major
cell
respons
elicit
nanoparticl
vaccin
target
follow
figur
data
demonstr
addit
robust
antibodi
respons
nanoparticl
vaccin
abl
prime
cellular
arm
immun
system
target
recombin
rbd
antigen
evalu
immunogen
protect
efficaci
safeti
nanoparticl
vaccin
infect
studi
use
highli
permiss
transgen
mice
briefli
aliquot
cdgmp
store
transport
oversea
assess
human
mice
upon
valid
nanoparticl
retain
expect
size
surfac
antigen
adjuv
encapsul
follow
storag
period
figur
support
inform
cdgmp
np
cdgmp
without
conjug
rbd
administ
subcutan
transgen
mice
day
day
figur
four
week
second
immun
sera
collect
determin
neutral
antibodi
titer
live
use
vero
microneutr
assay
compar
undetect
antibodi
respons
control
anim
averag
neutral
titer
rang
could
readili
detect
mous
immun
cdgmp
figur
tabl
support
inform
follow
intranas
challeng
strain
two
mice
group
euthan
postinfect
dpi
assess
viral
load
histopatholog
lung
wherea
remain
mice
monitor
daili
mortal
dpi
safeti
concern
immunopatholog
rais
infect
model
whole
inactiv
viru
wiv
recombin
even
modifi
vaccinia
viru
ankara
mva
vector
thoroughli
examin
patholog
chang
lung
specimen
challeng
mice
although
eosinophil
infiltr
could
readili
observ
either
group
figur
figur
support
inform
mice
immun
cdgmp
exhibit
mild
infiltr
lymphocyt
monocyt
compar
control
nanoparticl
figur
figur
support
inform
blue
arrow
exact
natur
inflammatori
respons
warrant
investig
specul
enhanc
respons
afford
nanoparticl
vaccin
might
given
potent
respons
induc
cdgmp
high
viral
titer
use
anim
challeng
like
lymphocyt
infiltr
correspond
local
recruit
lymphocyt
presenc
local
lymphocyt
report
contribut
protect
immun
respiratori
viral
titer
anim
sacrif
dpi
subsequ
assess
infecti
progeni
viru
recov
mice
immun
cdgmp
compar
moder
readili
detect
yield
infecti
viru
control
mice
figur
quantif
viral
load
quantit
analys
also
show
signific
reduct
amount
rna
cdgmp
mice
figur
demonstr
effect
contain
viral
spread
replic
furthermor
mice
immun
cdgmp
uniformli
surviv
dpi
upon
termin
studi
contrast
control
mice
succumb
infect
within
dpi
p
figur
result
pilot
studi
valid
efficaci
safeti
rbdcdgmp
vaccin
infect
diseas
addit
studi
warrant
comprehens
develop
vaccin
candid
emerg
infecti
threat
priorit
vaccin
research
promin
exampl
emerg
pathogen
urgent
public
health
need
prevent
measur
sporad
outbreak
diseas
continu
report
high
mortal
rate
clinic
approv
vaccin
pathogen
date
candid
includ
candid
qv
enter
clinic
trial
much
ongo
research
effort
vaccin
focus
recombin
protein
subunit
vaccin
owe
safeti
product
consist
present
studi
antigen
formul
synthet
nanoparticl
fashion
improv
vaccin
potenc
among
commonli
use
antigen
name
protein
fragment
rbd
rbd
herein
select
antibodi
domain
shown
greater
viru
neutral
potenti
compar
prior
studi
adopt
nanoparticl
fc
conjug
enhanc
immunogen
rbd
protein
poorli
present
nanoparticl
vaccin
integr
antigen
cdgmp
promot
antibodi
cell
respons
therebi
obviat
need
human
fc
conjug
lesson
learnt
vaccin
develop
well
prior
vaccin
studi
indic
immunolog
adjuv
particularli
adjuv
critic
improv
antigen
immunogen
reduc
eosinophil
immunopatholog
howev
administr
adjuv
formul
need
handl
caution
elev
level
immunogen
usual
come
cost
increas
system
inflammatori
respons
reactogen
safeti
concern
regard
adjuv
reactogen
motiv
ongo
develop
particul
adjuv
design
target
lymphat
system
better
promot
local
immun
respons
sting
agonist
adjuv
adopt
present
studi
sever
vehicl
includ
liposom
qv
calcium
phosphat
polymer
cation
appli
improv
molecul
potenc
safeti
prior
report
compar
aforement
sting
agonist
formul
hollow
polymer
nanoparticl
develop
herein
possess
combin
advantag
biocompat
size
consist
colloid
stabil
tunabl
adjuv
load
releas
antigen
functionaliz
favor
attribut
make
hollow
nanoparticl
desir
deliveri
platform
immun
modul
examin
np
cdgmp
show
mani
report
advantag
nanoparticul
adjuv
includ
effici
uptak
antigen
present
cell
enhanc
immunostimul
capabl
reduc
system
inflammatori
respons
attribut
expect
improv
immunogen
efficaci
safeti
applic
sting
agonist
vaccin
purpos
addit
recombin
viral
antigen
attach
nanoparticl
enabl
mimicri
natur
virion
effect
immun
potenti
induct
protect
immun
danger
signal
antigen
process
dendrit
cell
identifi
import
factor
selfnonself
codeliveri
antigen
adjuv
singl
carrier
shown
enhanc
immun
cell
activ
antigen
present
time
type
ifn
signal
antigen
present
also
observ
critic
influenc
immun
respons
wherea
ifn
signal
follow
antigen
present
signal
potent
stimul
cell
expans
cell
ifn
prior
antigen
present
signal
induc
inhibitori
find
highlight
signific
coordin
antigen
adjuv
deliveri
support
viromimet
vaccin
design
mechanist
basi
point
literatur
shown
excess
product
type
ifn
infect
detriment
effect
immun
adapt
immun
strongli
influenc
time
magnitud
type
ifn
sting
linger
concern
use
sting
agonist
vaccin
adjuv
given
pleiotrop
role
type
ifn
gener
accept
short
strong
type
ifn
respons
coordin
antigen
present
conduc
adapt
light
hollow
nanoparticl
offer
ideal
control
system
precis
gaug
dose
time
type
ifn
signal
robust
immun
respons
studi
warrant
system
evalu
concentr
antigen
adjuv
influenc
immun
activ
present
work
show
contrast
solubl
rbd
antigen
formul
free
sting
agonist
robust
sustain
antibodi
respons
observ
mice
immun
nanoparticl
vaccin
data
indic
viromimet
nanoparticul
vaccin
superior
abil
mount
humor
respons
compar
adjuv
influenza
vaccin
antibodi
gener
vaccin
capabl
neutral
directli
contribut
protect
immun
viral
challeng
moreov
nanoparticl
vaccin
induc
balanc
immun
respons
consist
prior
report
immun
stimul
qv
potent
respons
indic
high
level
antibodi
like
account
absenc
eosinophil
immunopatholog
notabl
nanoparticl
vaccin
highli
capabl
prime
cell
respons
thought
recoveri
infect
may
sole
correl
antibodi
respons
recent
literatur
show
increas
emphasi
role
cell
respons
especi
cell
protect
immun
futur
studi
dissect
humor
cellular
immun
respons
protect
warrant
sever
vaccin
candid
human
respiratori
coronaviru
includ
whole
inactiv
viru
wiv
recombin
rbd
subunit
protein
other
investig
permiss
mice
rabbit
nonhuman
primat
nhp
vaccin
candid
immunogen
effect
immun
anim
subsequ
live
viru
challeng
concern
safeti
regard
induct
immunopatholog
andor
diseas
enhanc
ade
immun
challeng
anim
exist
undesir
host
respons
character
enhanc
pulmonari
eosinophil
monocyt
infiltr
accompani
increas
recruit
complement
protein
without
sign
uncontrol
viral
note
passiv
transfer
sera
contain
antibodi
deriv
infect
rabbit
rabbit
result
exacerb
pulmonari
inflamm
accentu
safeti
concern
suboptim
host
respons
infect
andor
also
observ
live
challeng
highli
permiss
human
transgen
mice
immun
either
wiv
uniformli
caus
signific
increas
eosinophil
infiltr
within
recent
note
human
transgen
mice
immun
recombin
adenoviru
exhibit
vari
extent
perivascular
hemorrhag
within
lung
upon
challeng
despit
impress
immunogen
efficaci
lethal
studi
prototyp
mer
vaccin
immunogen
effect
inhibit
viral
infect
also
obviat
induct
undesir
lung
patholog
immun
challeng
human
transgen
mice
encourag
result
warrant
develop
vaccin
platform
model
pathogen
studi
also
demonstr
viromimet
nanoparticl
vaccin
design
may
applic
mani
viral
diseas
threaten
public
health
live
microb
long
provid
design
inspir
vaccin
present
work
advanc
concept
sting
hollow
nanoparticl
unlik
prior
report
nanoformul
inadequ
encapsul
capac
compound
hollow
plga
nanoparticl
present
herein
permit
tunabl
encapsul
control
releas
sting
agonist
cargo
nanoparticl
may
adjust
modul
immun
stimul
particl
functionaliz
allow
attach
differ
recombin
viral
antigen
tailor
specif
vaccin
need
consist
entir
biocompat
materi
nanoparticl
safe
administ
store
transport
upon
freez
although
need
cold
chain
transport
would
incur
addit
cost
anticip
public
health
benefit
outweigh
technolog
logist
invest
toward
futur
translat
scalabl
manufactur
expect
benefit
exist
infrastructur
recombin
protein
product
polymer
effect
coupl
viral
antigen
immunolog
adjuv
nanoparticl
vaccin
minim
safeti
concern
potenc
rival
viral
formul
envis
effect
prophylact
measur
highli
lethal
pathogen
stringent
safeti
efficaci
requir
yet
safetyefficaci
tradeoff
often
exist
among
commonli
adopt
vaccin
candid
use
synthet
biodegrad
polym
construct
hollow
nanoparticl
associ
subunit
antigen
adjuv
nanoengin
approach
demonstr
prepar
safe
potent
vaccin
formul
middl
east
respiratori
syndrom
coronaviru
pathogen
urgent
vaccin
need
studi
highlight
applic
synthet
nanoparticl
advanc
vaccin
technolog
emerg
infecti
threat
anim
mice
nation
laboratori
anim
center
taiwan
hous
anim
facil
maintain
institut
biomed
scienc
academia
sinica
femal
transgen
mice
express
human
gener
hous
barrier
facil
univers
texa
medic
branch
previous
experi
perform
approv
protocol
institut
anim
care
use
committe
iacuc
academia
sinica
offic
research
project
protect
iacuc
univers
texa
medic
branch
texa
cell
line
spodoptera
frugiperda
adapt
cell
purchas
invitrogen
cell
cultur
grace
medium
thermo
fisher
scientif
supplement
fetal
bovin
serum
fb
u
penicillin
streptomycin
cell
cultur
ii
serum
free
medium
thermo
fisher
scientif
contain
u
penicillin
streptomycin
murin
immatur
dendrit
jaw
ii
cell
obtain
american
type
cultur
collect
maintain
minimum
essenti
medium
mem
alpha
medium
contain
ribonucleosid
deoxyribonucleosid
fb
u
penicillin
streptomycin
sodium
pyruv
ng
murin
humidifi
incub
recombin
express
purif
dna
sequenc
encod
receptor
bind
domain
rbd
spike
antigen
histidin
tag
affin
purif
obtain
dna
synthesi
genscript
clone
gfp
vector
result
recombin
plasmid
first
amplifi
e
coli
transform
e
coli
gene
transposit
transpos
bacmid
purifi
transfect
prepar
baculovirus
carri
recombin
rbd
cell
transform
screen
coloni
pcr
appropri
primer
recombin
plasmid
verifi
sequenc
baculoviru
express
system
adopt
product
recombin
rbd
briefli
cell
infect
recombin
baculoviru
moi
incub
four
day
later
cultur
supernat
collect
centrifug
extracellular
rbd
protein
purifi
histrap
hp
column
ge
healthcar
use
fplc
system
purifi
protein
verifi
western
blot
mous
tag
antibodi
roch
antirecombin
rbd
rabbit
serum
protein
concentr
determin
bradford
assay
nanoparticl
vaccin
prepar
hollow
polymer
nanoparticl
prepar
use
doubl
emuls
process
polym
solut
prepar
dissolv
mg
carboxi
termin
poli
dl
correspond
da
respect
lactel
absorb
polym
dichloromethan
viscos
polym
solut
quantifi
use
microvisc
rheomet
rheosens
accord
manufactur
protocol
inner
aqueou
phase
prepar
dissolv
cdgmp
invivogen
phosphat
buffer
ph
typic
prepar
aqueou
solut
contain
cdgmp
emulsifi
polym
solut
ice
use
ultrason
probe
sonic
puls
mode
amplitud
durat
min
first
emuls
subsequ
ad
ml
phosphat
buffer
ph
probe
sonic
amplitud
durat
min
emuls
subsequ
pour
ml
water
heat
gentl
stir
fume
hood
solvent
evapor
prepar
hollow
nanoparticl
antigen
conjug
avanti
polar
lipid
inc
ad
ml
water
prior
addit
second
emuls
follow
h
solvent
evapor
nanoparticl
collect
use
kda
mwco
amicon
filter
conjug
recombin
rbd
antigen
nanoparticl
purifi
rbd
protein
mix
nanoparticl
solut
contain
mild
reduc
agent
tri
phosphin
tcep
typic
vaccin
prepar
rbd
antigen
mix
mg
hollow
nanoparticl
contain
cdgmp
ml
solut
compris
phosphat
buffer
ph
tcep
mixtur
incub
h
gentl
shake
room
temperatur
nanoparticl
isol
free
protein
use
kda
mwco
amicon
filter
nanoparticl
vaccin
store
freez
sucros
nanoparticl
vaccin
character
nanoparticl
concentr
evalu
nanoparticl
track
analysi
use
nanosight
malvern
instrument
nanoparticl
size
zeta
potenti
determin
dynam
light
scatter
dl
use
zetas
nano
zs
malvern
instrument
adjuv
retent
studi
perform
suspend
nanoparticl
pb
mg
eppendorf
tube
predetermin
time
point
nanoparticl
wash
amicon
filter
remov
releas
cdgmp
quantifi
cdgmp
content
cdgmp
releas
kinet
physiolog
relev
condit
character
dialysi
experi
two
differ
ph
environ
ph
nanoparticl
load
mini
dialysi
devic
kda
mwco
thermo
fisher
scientif
collect
predetermin
time
point
cdgmp
quantif
associ
nanoparticl
analyz
quantifi
peg
use
iodin
precipit
assay
recombin
rbd
protein
measur
use
bca
protein
assay
thermo
fisher
scientif
follow
manufactur
protocol
nanoparticl
visual
neg
stain
perform
uranyl
acet
immunogold
stain
perform
use
mous
tag
antibodi
roch
goat
antimous
igg
hl
antibodi
conjug
nm
colloid
gold
jackson
immunoresearch
west
grove
pa
neg
stain
immunogold
stain
sampl
visual
use
fei
kv
sphera
microscop
imag
acquir
use
tecnai
transmiss
electron
microscop
fei
compani
netherland
oper
acceler
voltag
kv
quantif
cdgmp
load
hplc
analysi
load
cdgmp
hollow
nanoparticl
quantifi
liquid
chromatographi
hplc
use
ascenti
express
column
briefli
hollow
nanoparticl
lyophil
aceton
ad
disrupt
plga
nanoparticl
remov
aceton
dri
bath
sampl
resuspend
follow
analysi
agil
seri
hplc
system
sampl
contain
cdgmp
retriev
nanoparticl
set
cdgmp
standard
analyz
use
gradient
hplc
method
start
mobil
phase
consist
mixtur
ammonium
acet
aa
acetonitril
second
mobil
phase
mixtur
aa
gradient
time
min
third
mobil
set
mixtur
aa
gradient
time
min
standard
calibr
curv
quantif
cdgmp
acquir
rang
valu
close
gener
bone
dendrit
cell
bmdc
bone
dendrit
cell
obtain
mice
accord
protocol
matheu
et
al
minor
briefli
bone
marrow
cell
harvest
femur
bone
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fb
ng
ng
cultur
medium
replac
day
cell
collect
experi
day
follow
flow
cytometr
analysi
harvest
cell
show
characterist
bmdc
immun
potenti
nanoparticl
vitro
vivo
cdgmp
biolog
lifesci
institut
use
cellular
uptak
studi
free
cdgmp
cdgmp
ad
jaw
ii
cell
h
incub
fluoresc
imag
acquir
olympu
vitro
immun
activ
jaw
ii
cell
plate
densiti
cell
per
well
plate
h
variou
concentr
free
cdgmp
cdgmp
ad
cell
cultur
supernat
harvest
h
h
follow
incub
cytokin
analysi
use
mous
uncoat
elisa
kit
thermo
fisher
scientif
mous
uncoat
elisa
kit
thermo
fisher
scientif
mous
elisa
kit
r
system
accord
manufactur
instruct
activ
marker
analysi
bone
dendrit
cell
incub
fcr
blocker
ice
min
follow
igg
isotyp
control
ebiosci
incub
ice
anoth
min
dark
incub
cell
wash
three
time
resuspend
ml
pb
flow
cytometr
analysi
use
fac
lsr
ii
bd
bioscienc
analysi
done
flowjo
softwar
tree
star
ashland
vivo
immun
potenti
analysi
free
cdgmp
cdgmp
inocul
mice
via
footpad
inject
variou
time
point
mice
sera
collect
poplit
lymph
node
homogen
dmem
cytokin
measur
mous
uncoat
elisa
kit
thermo
fisher
scientif
mous
elisa
kit
r
system
serum
homogen
imag
antigen
adjuv
deliveri
nanoparticl
jaw
ii
cell
incub
nanoparticl
contain
label
cdgmp
label
rbd
antigen
h
incub
remov
media
cell
wash
three
time
pb
fix
paraformaldehyd
follow
imag
olympu
fluoresc
microscop
vivo
distribut
modifi
method
adopt
report
gonzalez
et
al
qv
briefli
mice
inject
subcutan
abovement
cdgmp
rbd
label
nanoparticl
h
mous
inject
apc
antimous
antibodi
clone
biolegend
via
subcutan
rout
drain
lymph
node
harvest
min
drain
lymph
node
fix
paraformaldehyd
follow
imag
use
zeiss
lsm
confoc
microscopi
anim
immun
serum
collect
group
mice
immun
twice
day
subcutan
tail
base
one
follow
formul
rbd
nanoparticl
free
rbd
protein
mix
free
cdgmp
adjuv
invivogen
pb
mous
given
inoculum
mg
nanoparticl
contain
recombin
rbd
protein
cdgmp
free
rbd
free
cdgmp
free
rbd
design
time
point
blood
collect
facial
vein
bd
sst
microtain
bd
bioscienc
sera
obtain
centrifug
g
min
store
elisa
analysi
micropl
nunc
denmark
coat
overnight
purifi
recombin
rbd
protein
ng
per
well
room
temperatur
block
wv
skim
milk
bd
difco
spark
md
room
temperatur
h
serial
dilut
mous
sera
ad
well
incub
room
temperatur
h
follow
three
wash
dilut
goat
antimous
igg
hl
jackson
immunoresearch
ad
well
incub
room
temperatur
h
enzymat
reaction
carri
use
sureblu
reserv
tmb
microwel
peroxidas
substrat
kpl
gaithersburg
md
stop
addit
tmb
stop
solut
kpl
optic
densiti
nm
measur
use
autom
plate
reader
thermo
fisher
scientif
intracellular
cytokin
stain
flow
cytometr
analysi
spleen
lymph
node
collect
euthan
mice
analysi
cell
respons
intracellular
cytokin
stain
ic
singl
cell
prepar
spleen
lymph
node
plate
cell
per
well
plate
rbd
antigen
synthet
peptid
feakpsgsv
qvynfkrl
tvphnltti
asncyssl
ad
stimul
cell
respect
h
golgiplug
protein
transport
inhibitor
bd
bioscienc
san
jose
ca
ad
plate
incub
anoth
h
spun
remov
medium
cell
resuspend
dilut
clone
bd
bioscienc
dilut
clone
bd
bioscienc
antibodi
min
incub
ice
cell
wash
resuspend
cytofixcytoperm
solut
incub
ice
min
two
wash
cell
stain
dilut
apc
antibodi
clone
bd
bioscienc
overnight
cell
wash
three
time
acquisit
use
fac
lsr
ii
institut
biomed
scienc
academia
sinica
analysi
done
flowjo
softwar
background
determin
sampl
without
peptid
stimul
subtract
valu
present
test
sampl
neutral
assay
standard
vero
microneutr
assay
perform
approv
biosafeti
level
laboratori
determin
titer
neutral
antibodi
live
previous
briefli
serial
twofold
dilut
mous
sera
incub
infecti
strain
room
temperatur
h
transfer
confluent
vero
cell
cultiv
incub
h
neutral
capabl
mous
sera
determin
presenc
absenc
cytopath
effect
cpe
neutral
antibodi
titer
express
reciproc
highest
dilut
sera
complet
inhibit
cpe
well
challeng
studi
challeng
studi
conduct
within
approv
anim
laboratori
galveston
nation
laboratori
strictli
follow
approv
nou
anim
protocol
guidelin
regul
nation
institut
health
aaalac
studi
two
group
five
human
mice
immun
subcutan
twice
four
week
apart
either
rbd
nanoparticl
vaccin
control
nanoparticl
nanoparticl
thaw
water
bath
sampl
store
month
four
week
booster
mice
bled
assess
igg
neutral
antibodi
respons
prior
intranas
challeng
lethal
dose
strain
viral
challeng
mice
monitor
daili
clinic
manifest
ie
weight
loss
mortal
least
infect
two
five
mice
sacrif
day
postchalleng
assess
lung
viral
load
vero
infect
assay
quantit
pcr
previous
addit
lung
tissu
process
h
e
assess
histopatholog
previous
statist
analys
data
analyz
nonparametr
unpair
test
anova
follow
dunnett
multipl
comparison
test
use
graphpad
prism
graphpad
softwar
san
diego
ca
p
valu
smaller
consid
statist
signific
author
declar
conflict
interest
